Illumina Ventures leads €16M round for digital PCR firm Stilla Technologies

Stilla launched its digital Naica system in 2016 for quantifying DNA mutations. (Pixabay)

Illumina Ventures led a €16 million ($18 million) series A round for Stilla Technologies, a Paris-based developer of digital PCR solutions for genetic analysis.

The genomics-focused fund supported by Illumina was joined by Kurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds and Idinvest Partners.

RELATED: Illumina Ventures bumps up fund to $230M


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Stilla launched its digital Naica system in 2016, designed to precisely quantify DNA mutations for research organizations specializing in molecular biology.

“This additional financing will enable Stilla to accelerate the sales of the Naica system, launch our 2nd generation solution and begin clinically validating panels to be run on the system, with an initial focus in the field of oncology,” Stilla CEO and co-founder Rémi Dangla said in a statement.

So far, the tests have been used to help develop liquid biopsies for cancer and prenatal tests, the company said.

RELATED: Illumina buys PacBio to shore up DNA sequencing dominance

“The Stilla team has done an amazing job developing and launching the Naica system in Europe and Asia with a very limited amount of seed financing,” said Nick Naclerio, founding partner of Illumina Ventures, who joined the company’s board of directors alongside representatives from Kurma and LBO France.

“With these additional resources, we believe that Stilla Technologies can become a global leader in digital PCR and the lowest cost platform for liquid biopsies,” Naclerio added.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.